Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Holzer

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Chimia|October 27, 2017
Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer DrugsPhilipp Holzer
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2005
Blocking the PI3K/PKB pathway in tumor cellsFrédéric Stauffer, Philipp Holzer, Carlos García-Echeverría
Journal of Inorganic Biochemistry|March 19, 2002
A supramolecular enzyme model catalyzing the central cleavage of carotenoidsRichard R French, Philipp Holzer, Michele Leuenberger, et al.
Kidney International|March 9, 2012
Podocyte EphB4 signaling helps recovery from glomerular injuryMonika Wnuk, Ruslan Hlushchuk, Mathilde Janot, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2015
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding modeFrançois Gessier, Joerg Kallen, Edgar Jacoby, et al.
Angiogenesis|August 31, 2010
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesisGeorg Martiny-Baron, Philipp Holzer, Eric Billy, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2016
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argumentPascal Furet, Keiichi Masuya, Joerg Kallen, et al.
Nature Communications|February 10, 2021
p53 dynamics vary between tissues and are linked with radiation sensitivityJacob Stewart-Ornstein, Yoshiko Iwamoto, Miles A Miller, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2018
Discovery of amino-1,4-oxazines as potent BACE-1 inhibitorsSiem Jakob Veenstra, Heinrich Rueeger, Markus Voegtle, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2018
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitorAndrea Vaupel, Philipp Holzer, Stephane Ferretti, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Chimia|October 27, 2017
Discovery of Potent and Selective p53-MDM2 Protein-Protein Interaction Inhibitors as Anticancer DrugsPhilipp Holzer
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2005
Blocking the PI3K/PKB pathway in tumor cellsFrédéric Stauffer, Philipp Holzer, Carlos García-Echeverría
Journal of Inorganic Biochemistry|March 19, 2002
A supramolecular enzyme model catalyzing the central cleavage of carotenoidsRichard R French, Philipp Holzer, Michele Leuenberger, et al.
Kidney International|March 9, 2012
Podocyte EphB4 signaling helps recovery from glomerular injuryMonika Wnuk, Ruslan Hlushchuk, Mathilde Janot, et al.
Bioorganic & Medicinal Chemistry Letters|July 5, 2015
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding modeFrançois Gessier, Joerg Kallen, Edgar Jacoby, et al.
Angiogenesis|August 31, 2010
The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesisGeorg Martiny-Baron, Philipp Holzer, Eric Billy, et al.
Bioorganic & Medicinal Chemistry Letters|August 21, 2016
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argumentPascal Furet, Keiichi Masuya, Joerg Kallen, et al.
Nature Communications|February 10, 2021
p53 dynamics vary between tissues and are linked with radiation sensitivityJacob Stewart-Ornstein, Yoshiko Iwamoto, Miles A Miller, et al.
Bioorganic & Medicinal Chemistry Letters|May 17, 2018
Discovery of amino-1,4-oxazines as potent BACE-1 inhibitorsSiem Jakob Veenstra, Heinrich Rueeger, Markus Voegtle, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2018
In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitorAndrea Vaupel, Philipp Holzer, Stephane Ferretti, et al.
Pageof 3